Anaemic.net – Page 2 – Anaemic.net is an available dictionary domain

Worldwide Iron Deficiency Anemia Pipeline 2020 – Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook

DUBLIN–(BUSINESS WIRE[1])–The “Iron Deficiency Anemia Pipeline Research Monitor, 2020 – Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook”[2] report has been added to ResearchAndMarkets.com’s offering. PIPELINE HIGHLIGHTS Iron Deficiency Anemia is one of the widely researched conditions during 2020 with 13 companies actively focusing on realizing pipeline’s potential. Development of Iron Deficiency Anemia medicines is identified as integral...

Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis

CAMBRIDGE, Mass., May 5, 2020 /PRNewswire/ — Akebia Therapeutics, Inc. [1](Nasdaq: AKBA[2]), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced positive top-line results from INNO2VATE, the first of its two global Phase 3 cardiovascular outcomes programs. The two INNO2VATE studies evaluated the efficacy and safety of vadadustat, Akebia’s investigational oral hypoxia-inducible factor prolyl hydroxylase...

Pharmacosmos Therapeutics Inc. established as a new specialty pharmaceutical company to bring recently approved treatment option to iron deficiency anemia patients

MORRISTOWN, N.J., Feb. 10, 2020 /PRNewswire/ — Pharmacosmos Therapeutics Inc. announced today that it has been established as a newly formed specialty pharmaceutical company dedicated to commercializing Monoferric® for Iron Deficiency Anemia (IDA) patients in the US. The new company is a subsidiary of the Pharmacosmos Group, a profitable, fast-growing specialty pharmaceutical company headquartered in Denmark. Monoferric® is an intravenous...

Research Reveals Promising New Avenues for Anemia Treatment

MANHASSET, N.Y.–(BUSINESS WIRE[1])–Nearly 1.6 billion people worldwide suffer from anemia, and for the first time new research points to how resistance emerges to the drug dexamethasone used to treat the devastating inherited form of anemia known as Diamond Blackfan anemia (DBA). The Feinstein Institutes for Medical Research[2] professor and expert in disorders of the red cell Lionel Blanc, PhD,[3] published...